Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) EBIT Margin: 2009-2025

Historic EBIT Margin for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -8,613.38%.

  • Cytokinetics' EBIT Margin rose 2179721.00% to -8,613.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -671.79%, marking a year-over-year increase of 1562600.00%. This contributed to the annual value of -3,574.99% for FY2024, which is 301472.00% up from last year.
  • Latest data reveals that Cytokinetics reported EBIT Margin of -8,613.38% as of Q3 2025, which was down 5,057.63% from -167.00% recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' EBIT Margin ranged from a high of -12.22% in Q2 2022 and a low of -52,277.91% during Q2 2024.
  • For the 3-year period, Cytokinetics' EBIT Margin averaged around -15,828.32%, with its median value being -9,856.30% (2025).
  • Per our database at Business Quant, Cytokinetics' EBIT Margin plummeted by 3,820,075bps in 2024 and then surged by 5,211,091bps in 2025.
  • Cytokinetics' EBIT Margin (Quarterly) stood at -39.57% in 2021, then crashed by 645,149bps to -6,491.06% in 2022, then tumbled by 112,964bps to -7,620.69% in 2023, then spiked by 669,376bps to -926.93% in 2024, then surged by 2,179,721bps to -8,613.38% in 2025.
  • Its EBIT Margin was -8,613.38% in Q3 2025, compared to -167.00% in Q2 2025 and -9,856.30% in Q1 2025.